Foghorn Therapeutics (FHTX) Invested Capital (2019 - 2021)
Foghorn Therapeutics (FHTX) posted quarterly Invested Capital of $300000.0 for Q2 2021, little changed quarter-over-quarter from $300000.0 in Q1 2021.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Invested Capital (2019 - 2021) Analysis & Trends
Foghorn Therapeutics' Invested Capital history runs 3 years deep, the most recent figure standing at $300000.0 for Q2 2021.
- In Q2 2021, Invested Capital changed N/A year-over-year to $300000.0; the TTM figure through Mar 2022 stood at $300000.0 (down 95.23% YoY), while the FY2019 annual figure was $4.2 million, changed N/A from the prior year.
- Invested Capital for Q2 2021 stood at $300000.0, roughly flat from $300000.0 in the prior quarter.
- The five-year high for Invested Capital was $6.0 million in Q3 2020, with the low at $300000.0 in Q1 2021.
- The 3-year median for Invested Capital is $2.2 million (2019), against an average of $2.7 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Foghorn Therapeutics | 346.08 Mn | 278.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 96.87 Mn |
| Sep 30, 2021 | 100.90 Mn |
| Jun 30, 2021 | 124.02 Mn |
| Mar 31, 2021 | 144.90 Mn |
| Dec 31, 2020 | 165.84 Mn |
| Sep 30, 2020 | -118.53 Mn |
| Dec 31, 2019 | -72.90 Mn |